Scholarlink

<p>In September 2024, the Food and Drug Administration (FDA) approved two novel therapeutic agents, Miplyffa (arimoclomol) in combination with Miglustat and Aqneursa (levacetylleucine), for Niemann-Pick Disease Type C (NPC), a rare and progressive lysosomal storage disorder with limited treatment options. NPC results from mutations in the NPC1 or NPC2 genes that impair intracellular cholesterol trafficking, leading to debilitating neurological and systemic symptoms. Miplyffa upregulates CLEAR genes and enhances the transcription of heat shock proteins, especially HPS 70 which are essential for proper NPC1 folding, stabilizes lysosomal membrane, enhances sphingolipid-degrading enzyme activity, and prevents cellular death. Aqneursa regulates energy metabolism, enhances mitochondrial and lysosomal function, and provides neuroprotective effects. Clinical trials have demonstrated that both drugs slow disease progression and improve patients’ quality of life. These approvals represent a major advancement in NPC treatment, offering hope to patients and their families and emphasizing the importance of continued research.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

FDA approves Miplyffa and Aqneursa: a new era in treatment of Niemann-Pick Disease Type C

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月1日

查看全文
  • Rizwana Noor,
  • Muhammad Saeed Qazi

摘要

In September 2024, the Food and Drug Administration (FDA) approved two novel therapeutic agents, Miplyffa (arimoclomol) in combination with Miglustat and Aqneursa (levacetylleucine), for Niemann-Pick Disease Type C (NPC), a rare and progressive lysosomal storage disorder with limited treatment options. NPC results from mutations in the NPC1 or NPC2 genes that impair intracellular cholesterol trafficking, leading to debilitating neurological and systemic symptoms. Miplyffa upregulates CLEAR genes and enhances the transcription of heat shock proteins, especially HPS 70 which are essential for proper NPC1 folding, stabilizes lysosomal membrane, enhances sphingolipid-degrading enzyme activity, and prevents cellular death. Aqneursa regulates energy metabolism, enhances mitochondrial and lysosomal function, and provides neuroprotective effects. Clinical trials have demonstrated that both drugs slow disease progression and improve patients’ quality of life. These approvals represent a major advancement in NPC treatment, offering hope to patients and their families and emphasizing the importance of continued research.